Apellis Pharmaceuticals develops first‑in‑class C3‑targeted inhibitors to treat diseases caused by overactivation of the complement system. Its approved drug pegcetacoplan (SYFOVRE®/EMPAVELI®) blocks all three complement pathways and is used for geographic atrophy, paroxysmal nocturnal hemoglobinuria, and complement‑mediated kidney disorders, while its pipeline extends C3 inhibition to additional rare and renal diseases.

Arcellx develops cell therapies utilizing its proprietary D-Domain technology and ddCAR platform to enhance the efficacy of immune cell treatments for cancer. The company targets relapsed or refractory multiple myeloma, aiming to provide patients with durable responses through its innovative CART-ddBCMA therapy.

Arvinas uses a proprietary PROTAC discovery engine to design bifunctional molecules that recruit E3 ubiquitin ligases and trigger proteasomal degradation of disease‑relevant proteins, expanding the druggable proteome for oncology and neurodegenerative indications. The company advances clinical‑stage degraders and offers partnership models for pharmaceutical and biotechnology companies to co‑develop or license these targeted protein‑degradation therapeutics.

Axonis Therapeutics is developing first-in-class oral KCC2 potentiator drugs, specifically targeting the KCC2 protein to restore functional inhibition in the brain. This approach aims to address neurological disorders such as epilepsy and pain by enhancing inhibitory signaling within the central nervous system.

Carbonbio's website does not provide details about its product or service.

Carisma Therapeutics develops chimeric antigen receptor macrophages (CAR-Macrophages) to target solid tumors by engineering a patient's own immune cells to enhance tumor infiltration and activate anti-tumor immunity. This approach addresses the challenges of immunosuppressive tumor microenvironments and antigen heterogeneity, offering a potential long-term treatment strategy for cancer patients.

Chameleon Biosciences is developing a re-dosable gene therapy using adeno-associated virus (AAV) technology to provide targeted and repeatable treatment options for genetic disorders. This approach addresses the limitations of traditional gene therapies, which often require a single administration and lack flexibility in treatment regimens.

Clearside BioMedical specializes in the suprachoroidal administration of therapeutic products to treat retinal diseases, utilizing a proprietary method that allows drugs to be precisely delivered to the back of the eye. Their FDA-approved product, XIPERE®, targets macular edema associated with uveitis, addressing the need for effective treatments in this area.

Ensoma develops one-time, off-the-shelf, in vivo treatments that utilize advanced hematopoietic stem cell engineering to precisely modify cells within the hematopoietic system. This technology aims to provide durable cures for genetic, immune, and oncological diseases by addressing the limitations of traditional therapies that often require multiple treatments.

EvolveImmune develops novel cancer immunotherapies using its proprietary EVOLVE platform to create trispecific T cell engagers with integrated CD2 costimulation. This approach is designed to overcome resistance mechanisms seen with existing immunotherapies. The company is advancing its lead candidate, EVOLVE104, into clinical trials for solid tumors.

This company pioneers a new approach to allosteric drug discovery by targeting natural hotspots on proteins to create differentiated medicines. Their proprietary Smart Allostery™ platform integrates structural biology, pharmacology, chemistry, and AI to systematically identify and drug these cellular on/off switches. The resulting novel allosteric medicines are being developed to treat diseases such as cancer and autoimmune disorders.

Immunitas Therapeutics utilizes single-cell genomics to develop targeted antibody-based therapies for cancer and autoimmune diseases, focusing on the CD161-CLEC2D pathway. Their lead candidate, IMT-009, is currently in clinical trials for treating refractory tumors, addressing the need for effective treatments in patients with limited options.

Kezar Life Sciences develops selective immunoproteasome inhibitors to modulate immune responses in autoimmune disorders, such as lupus nephritis and autoimmune hepatitis. Their approach targets protein homeostasis to halt the secretion of disease-promoting proteins, offering a therapeutic alternative to direct immunosuppression.

Kymera Therapeutics specializes in targeted protein degradation to develop therapeutics that directly eliminate disease-causing proteins. This approach enables the treatment of a wide range of diseases by addressing the underlying mechanisms of illness, offering new options for patients with unmet medical needs.

Maxion Therapeutics utilizes its patented KnotBody® technology to develop engineered antibody therapeutics targeting ion channel and GPCR-driven diseases, which are often inadequately treated by existing small molecule drugs. The company focuses on creating safe, effective, and long-acting treatments for chronic pain, autoimmune disorders, and cardiovascular diseases, addressing a significant unmet medical need for over 1.8 billion patients worldwide.

Orionis Biosciences develops conditionally acting medicines using its A-KINE® and ALLO-GLUE™ platforms, which leverage targeted cytokine immunotherapies and allosteric molecular glues to enhance immune responses against cancer and other diseases. The company addresses the challenge of treating solid tumors by advancing its first-in-class reprogrammed interferon cytokine, ORB-011, currently in Phase 1 clinical trials.

Rallybio develops monoclonal antibodies targeting rare diseases, focusing on conditions like Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). The company aims to provide effective treatment options that have been historically unavailable for patients suffering from these debilitating conditions.

ReCode Therapeutics utilizes its Selective Organ Targeting (SORT) lipid nanoparticle platform to deliver mRNA and gene correction therapies directly to specific organs and tissues, bypassing the liver. The company focuses on developing treatments for genetically defined diseases, such as primary ciliary dyskinesia and cystic fibrosis, where no effective therapies currently exist.

Seer provides the Proteograph™ platform, which utilizes a novel technology to enable deep, unbiased proteomics studies at scale, allowing researchers to analyze complex biological samples with enhanced throughput and coverage. This platform addresses the limitations of traditional proteomics methods by facilitating the identification of low-abundance proteins critical to understanding health and disease.

Synlogic develops synthetic biotic medicines that utilize engineered living therapeutics to perform specific metabolic functions, targeting diseases such as phenylketonuria (PKU). By addressing the underlying metabolic deficiencies, these biotherapeutics aim to transform treatment approaches and improve patient outcomes.

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

Xilio Therapeutics develops tumor-activated immuno-oncology therapies using proprietary platform technology to create targeted molecules that enhance anti-tumor activity within the tumor microenvironment. This approach aims to provide effective treatment options for patients with solid tumors while minimizing systemic side effects associated with traditional immuno-oncology therapies.